SECUKINUMAB (Cosentyx) prior authorization at Priority Health
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Priority Health requires Interleukin-17A Antagonist prior-authorization documentation for SECUKINUMAB (Cosentyx): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Priority Health reviews SECUKINUMAB (Cosentyx) prior authorizations against its medical policy for Interleukin-17A Antagonist. Priority Health-specific context: Subsidiary of Corewell Health (Michigan integrated health system, formed from Beaumont + Spectrum 2022); ~1.3M members. Second-largest insurer in Michigan after BCBS Michigan. Michigan DIFS oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Interleukin-17A Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Priority Health's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- West Michigan narrow-network restrictions
- Step therapy on specialty drugs
- Medicare Advantage Part B drug step therapy
- Behavioral health network adequacy
SECUKINUMAB (Cosentyx)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring TNF-inhibitor before IL-17
- PASI score threshold not documented
- Indication-specific PA (PsA vs ankylosing spondylitis vs HS)
- Non-formulary in favor of IL-23 class
Brand: Cosentyx. IL-17A inhibitor. Expanded indications now include moderate-to-severe hidradenitis suppurativa (FDA approval October 2023). Self-administered subQ; loading then monthly maintenance.
Manufacturer patient-assistance program: Cosentyx Connect — relevant when a Priority Health denial sticks and the patient needs bridge access while appealing.
How Priority Health approaches Biologic drugs (mAbs and biosimilars) PAs
For SECUKINUMAB (COSENTYX), check whether the current Priority Health Biologic drugs (mAbs and biosimilars) policy cites step therapy on specialty drugs or medicare advantage part b drug step therapy. Pharmacy-benefit review for SECUKINUMAB (COSENTYX) at Priority Health is routed through Express Scripts. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Priority Health; if denied, use the filing date and route printed on that denial notice. Priority Health's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Priority Health is domiciled in MI, so unresolved appeals escalate to the MI insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.priorityhealth.com/provider) with the same packet plus an applicable, current clinical source supporting SECUKINUMAB (Cosentyx)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Priority Health denial on DenialHelp.
Contact Priority Health
- Provider portal: https://www.priorityhealth.com/provider
Frequently asked questions
What documentation does Priority Health need for SECUKINUMAB (Cosentyx) prior auth?
Priority Health's typical PA packet for SECUKINUMAB (Cosentyx): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Interleukin-17A Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Priority Health?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for SECUKINUMAB (Cosentyx) at Priority Health?
Preparation scenarios to check against the current notice and policy include: West Michigan narrow-network restrictions; Step therapy on specialty drugs; Medicare Advantage Part B drug step therapy. These are not measured frequency claims. For SECUKINUMAB (Cosentyx), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does Priority Health typically require before approving SECUKINUMAB (COSENTYX)?
Priority Health's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For SECUKINUMAB (COSENTYX), attach the specific disease-activity instrument Priority Health accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for Priority Health fully-insured policies sits with the MI insurance department.
How do I prep for a peer-to-peer with Priority Health on SECUKINUMAB (Cosentyx)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the SECUKINUMAB (Cosentyx) PA packet
Open ApprovalHelp — generate a SECUKINUMAB (Cosentyx) prior-auth packet tailored to Priority Health's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com